There are plenty of anecdotes and statistics underscoring how pitifully biotechnology stocks and the relevant exchange-traded funds have performed this year, but this one sums it all up quite nicely: Of the five biotech ETFs that existed prior to 2014, the best performer this year is the Market Vectors Biotech ETF (NASDAQ: BBH), and that ETF is down 20.1 percent.
That is good enough to put BBH in a bear market less than two months into 2016. Despite the biotech space's obvious struggles to start 2016, some traders are not shy about expressing bullish views. For example, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB), the largest biotech ETF, has added nearly $81 million in new assets ...
/www.benzinga.com/general/biotech/16/02/6407441/some-traders-arent-shy-about-betting-on-a-biotech-rebound alt=Some Traders Aren't Shy About Betting On A Biotech Rebound>Full story available on Benzinga.com
More...